Clinical trials
Terminated Staphylococcal Infections trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
23 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 4 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2018 | 3 |
| 2019 | 2 |
| 2020 | 2 |
| 2022 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 23 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 2 |
| Aridis Pharmaceuticals, Inc. | 1 |
| Arsanis, Inc. | 1 |
| Centre Hospitalier Universitaire de Nice | 1 |
| Centre Hospitalier Universitaire de Saint Etienne | 1 |
| Cumberland Pharmaceuticals | 1 |
| DermBiont, Inc. | 1 |
| Hospices Civils de Lyon | 1 |
| Merck Sharp & Dohme LLC | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Staphylococcal Infections | 23 |
| Bacteremia | 6 |
| Dermatitis, Atopic | 2 |
| Endocarditis | 2 |
| Gram-Positive Bacterial Infections | 2 |
| Pneumonia, Ventilator-Associated | 2 |
| Cross Infection | 1 |
| Disease | 1 |
| Endocarditis, Bacterial | 1 |
| Escherichia coli Infections | 1 |
Trials
Showing 1 to 23 of 23. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.